Cardiovascular disease in chronic kidney disease
暂无分享,去创建一个
[1] F. Dekker,et al. Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. , 2006, Journal of the American Society of Nephrology : JASN.
[2] J. A. Brown,et al. Glomerular Filtration Rate , 1967 .
[3] Harlan M Krumholz,et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. , 2004, Journal of the American Society of Nephrology : JASN.
[4] B. Freedman,et al. Population-Based Screening for Family History of End-Stage Renal Disease among Incident Dialysis Patients , 2005, American Journal of Nephrology.
[5] J. Singer,et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] R. Garrick. Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease , 2008 .
[7] T. Uzu,et al. Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes , 2007, Diabetes.
[8] T. Hostetter,et al. Staging of chronic kidney disease: time for a course correction. , 2008, Journal of the American Society of Nephrology : JASN.
[9] R. Garrick. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency , 2008 .
[10] A. Garg,et al. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. , 2002, Kidney international.
[11] Charles E. McCulloch,et al. CHRONIC KIDNEY DISEASE AND THE RISKS OF DEATH, CARDIOVASCULAR EVENTS, AND HOSPITALIZATION , 2004 .
[12] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[13] J. Kaufman,et al. Age affects outcomes in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.
[14] P. Whelton,et al. The Prevalence of Nontraditional Risk Factors for Coronary Heart Disease in Patients with Chronic Kidney Disease , 2004, Annals of Internal Medicine.
[15] G. Filler,et al. Cystatin C as a marker of GFR--history, indications, and future research. , 2005, Clinical biochemistry.
[16] Amy Barreras,et al. Angiotensin Ii Receptor Blockers , 2003, Proceedings.
[17] G. Remuzzi,et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.
[18] G. Bakris,et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.
[19] R. Garrick. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy , 2009 .
[20] J. Gross,et al. Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.
[21] F. Locatelli,et al. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .
[22] M. Glickman,et al. Blood Pressure and Survival in the Oldest Old , 2007, Journal of the American Geriatrics Society.
[23] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[24] G. Eknoyan,et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[25] H. Parving,et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus , 2007, Journal of hypertension.
[26] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.
[27] H. Parving,et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.
[28] T. Berl,et al. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. , 2005, Clinical journal of the American Society of Nephrology : CJASN.
[29] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[30] Donald R. Miller,et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. , 2008, Archives of internal medicine.
[31] J. Griffith,et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] Robert M Califf,et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.
[33] L. Hunsicker. The consequences and costs of chronic kidney disease before ESRD. , 2004, Journal of the American Society of Nephrology : JASN.
[34] R. Foley,et al. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. , 2007, Journal of the American Society of Nephrology : JASN.
[35] M. Pfeffer,et al. Cardiovascular risk in chronic kidney disease. , 2004, Kidney international. Supplement.
[36] S. Reis,et al. Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women , 2002, Circulation.
[37] M. Weir. Microalbuminuria and cardiovascular disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[38] Steven Shea,et al. Risk Factors for the Progression of Coronary Artery Calcification in Asymptomatic Subjects: Results From the Multi-Ethnic Study of Atherosclerosis (MESA) , 2007, Circulation.
[39] Deeb N Salem,et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.
[40] M. Shlipak,et al. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. , 2003, Journal of the American Society of Nephrology : JASN.
[41] Keith C. Norris,et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). , 2007, Archives of internal medicine.
[42] P. Ruggenetu. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) , 1998 .
[43] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[44] J. Griffith,et al. Cardiovascular disease and subsequent kidney disease. , 2007, Archives of internal medicine.
[45] A. Garg,et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.
[46] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[47] Michael M Engelgau,et al. Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan , 2006, Preventing chronic disease.
[48] B. Kestenbaum,et al. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. , 2006, Kidney international.
[49] H. Trivedi,et al. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[50] F. Locatelli,et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.
[51] L. Cooper,et al. USRDS. 2001 Annual Data Report. , 2001, Nephrology news & issues.
[52] A. Go,et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.
[53] W. Keane,et al. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. , 2004, Kidney international. Supplement.
[54] B. Palmer. Supratherapeutic Doses of Angiotensin Receptor Blockers to Decrease Proteinuria in Patients with Chronic Kidney Disease , 2007, American Journal of Nephrology.
[55] B. Brenner,et al. Renal risk scores: progress and prospects. , 2008, Kidney international.
[56] E. Lewis,et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[57] G. Becker,et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[58] Charles E. McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[59] J. Kalus,et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[60] T. Dubose. American Society of Nephrology Presidential Address 2006: chronic kidney disease as a public health threat--new strategy for a growing problem. , 2007, Journal of the American Society of Nephrology : JASN.
[61] J. Coresh,et al. Prevalence of chronic kidney disease in the United States. , 2007, JAMA.
[62] D. Charytan,et al. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. , 2006, Kidney international.
[63] C. Gullion,et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.
[64] J. Coresh,et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. , 2003, Kidney international.
[65] F. Hsu,et al. The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study , 2005, Diabetologia.
[66] L. Kuller,et al. Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. , 2008, Atherosclerosis.
[67] K. Norris,et al. Racial differences in mortality among those with CKD. , 2008, Journal of the American Society of Nephrology : JASN.
[68] B. Freedman,et al. Chronic kidney disease: cause and consequence of cardiovascular disease. , 2007, Archives of internal medicine.
[69] C. Jurkovitz,et al. Screening for chronic kidney disease: unresolved issues. , 2003, Journal of the American Society of Nephrology : JASN.